Amgen's autoimmune drug succeeds in late-stage trial

By Reuters News

Sept 22 (Reuters) - Amgen AMGN.O said on Tuesday its experimental drug to treat an autoimmune disease that attacks the body's moisture-producing glands met the main goal of reducing disease activity in a late-stage trial.


Here are some details:

  • The drug dazodalibep showed statistically significant and clinically meaningful improvement in patients with Sjogren's disease at week 48.

  • Sjogren's disease can cause extensive dryness of the eyes, mouth and other parts of the body, along with fatigue and chronic pain.

  • It affects about 1% of the global population and predominantly affects women, according to the National Institutes of Health.

  • Amgen said most adverse events in the trial were mild to moderate, with few patients discontinuing treatment.

  • Novartis NOVN.S and Johnson & Johnson JNJ.N are also developing drugs to treat Sjogren's disease, which has no approved treatments in the US.

  • Amgen plans to present detailed data from the trial at an upcoming medical meeting. The trial is expected to be completed in the fourth quarter of 2026.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.